Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8692811 | 0.92 | KDM4E (0.43) | SMN1; SMN2KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL12590746 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL2062770 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL12590776 | 0.81 | CYP1A2 (0.44) | SMN1; SMN2TDP1L3MBTL1TSHRHSD17B10 | |
| SCHEMBL5844147 | 0.80 | MAPK1 (0.46) | KDM4ELMNAKMT2AMEN1MAPK1 | |
| SCHEMBL1748473 | 0.80 | MAPK1 (0.46) | KDM4ELMNAKMT2AMEN1MAPK1 | |
| SCHEMBL2063964 | 0.80 | MAPK1 (0.46) | SMN1; SMN2KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL30959611 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAKMT2AMEN1MAPK1 | |
| SCHEMBL1055154 | 0.79 | MAPK1 (0.53) | SMN1; SMN2KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL12000330 | 0.78 | KDM4E (0.41) | SMN1; SMN2KDM4ELMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118440011-A | Purification method of 4, 6-dichloropyrimidine or derivative thereof | 诚达药业股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-118440010-A | Preparation method of 4, 6-dichloro-5-pyrimidine acetaldehyde | 诚达药业股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-102216302-B | Akt and p70 s6 kinase inhibitors | LILLY CO ELI | 2013-08-21 | — | — | CN | disclosed |
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102216302-A | Akt and p70 s6 kinase inhibitors | LILLY CO ELI | 2011-10-12 | — | — | CN | disclosed |
| US-7968536-B2 | Heterocyclic compounds useful as RAF kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968536-B2 | Heterocyclic compounds useful as RAF kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2010056563-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | SMN1; SMN2 3551/4885KDM4E 2390/4885LMNA 4229/4885 |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | SMN1; SMN2 4436/4885KDM4E 2207/4885LMNA 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.